Status:

COMPLETED

Study to Evaluate D-1553 in Subjects With Lung Cancer

Lead Sponsor:

InventisBio Co., Ltd

Conditions:

NSCLC

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

This is a phase 1/2, open label study of D-1553 single agent treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects...

Eligibility Criteria

Inclusion

  • Subject with histologically proven, locally advanced, unresectable and/or metastatic NSCLC for which no standard treatment is available or the subject is refractory to or intolerant of existing standard treatment.
  • Subject has KRasG12C mutation in tumor tissue or other biospecimens containing cancer cells or DNA. Historical, local laboratory result (up to 5 years prior to this study) can be used for Phase 1 subjects. Phase 2 subjects must be tested for KRasG12C mutation by a central laboratory.
  • Subject has measurable disease according to RECIST, v1.1

Exclusion

  • Subject with unstable or progressive central nervous system (CNS) metastases.
  • Subjects with clinically significant cardiovascular disease
  • Subject with interstitial lung disease (ILD) or any active systemic infection including but not limited to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
  • Subject has impaired gastrointestinal (GI) function or GI diseases that may significantly alter the absorption or metabolism of oral medications.
  • Subject is pregnant or lactating.

Key Trial Info

Start Date :

March 16 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 17 2024

Estimated Enrollment :

225 Patients enrolled

Trial Details

Trial ID

NCT05383898

Start Date

March 16 2021

End Date

May 17 2024

Last Update

October 15 2024

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Shanghai Chest Hospital

Shanghai, Shanghai Municipality, China, 200030

2

Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences,

Hangzhou, Zhejiang, China, 310005